Asset Details
Do you wish to reserve the book?
Alemtuzumab for haematological malignancies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Alemtuzumab for haematological malignancies
Do you wish to request the book?
Alemtuzumab for haematological malignancies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Alemtuzumab for haematological malignancies
2025
Overview
Alemtuzumab is a humanized recombinant monoclonal antibody that specifically targets the CD52 antigen, which is expressed on both malignant and normal T and B lymphocytes. By binding to CD52, alemtuzumab exerts potent antitumor and immunosuppressive effects. Initially approved by the FDA in 2001 for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), alemtuzumab’s therapeutic applications have expanded to various hematologic malignancies, including lymphoma, acute leukemia, myelodysplastic syndromes (MDS), aplastic anemia (AA), graft-versus-host disease (GVHD), and chimeric antigen receptor T-cell (CAR-T) therapy. This review evaluates the efficacy and safety of alemtuzumab in these conditions, aiming to synthesize current evidence and provide guidance for clinical practice to optimize the use of alemtuzumab in the treatment of these diseases.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Alemtuzumab - therapeutic use
/ Anemia, Aplastic - drug therapy
/ Antigens
/ Antineoplastic Agents, Immunological - adverse effects
/ Antineoplastic Agents, Immunological - therapeutic use
/ Graft vs Host Disease - drug therapy
/ Hematologic Neoplasms - drug therapy
/ Hematologic Neoplasms - immunology
/ Humans
/ Leukemia
/ Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
/ Lymphoma
/ Medicine
/ Myelodysplastic Syndromes - drug therapy
/ Oncology
/ Patients
/ Review
